

**INTERNATIONAL TRADE
COMMISSION**

[Investigation Nos. 731-TA-1369-1372
(Final)]

**Fine Denier Polyester Staple Fiber
From China, India, Korea, and Taiwan;
Supplemental Schedule for the Subject
Investigations**

AGENCY: United States International
Trade Commission.

ACTION: Notice.

DATES: May 30, 2018.

FOR FURTHER INFORMATION CONTACT:
Jordan Harriman (202-205-2610), Office
of Investigations, U.S. International
Trade Commission, 500 E Street SW,
Washington, DC 20436. Hearing-
impaired persons can obtain
information on this matter by contacting
the Commission's TDD terminal on 202-
205-1810. Persons with mobility
impairments who will need special
assistance in gaining access to the
Commission should contact the Office
of the Secretary at 202-205-2000.
General information concerning the
Commission may also be obtained by
accessing its internet server ([https://
www.usitc.gov](https://www.usitc.gov)). The public record for
these investigations may be viewed on
the Commission's electronic docket
(EDIS) at <https://edis.usitc.gov>.

SUPPLEMENTARY INFORMATION: Effective
November 6, 2017, the Commission
established a general schedule for the
conduct of the final phase of its
investigations on fine denier polyester
staple fiber ("fine denier PSF") from
China, India, Korea, and Taiwan,¹
following preliminary determinations
by the U.S. Department of Commerce
("Commerce") that imports of fine
denier PSF were subsidized by the
governments of China and India. To
date, Commerce has issued final
affirmative countervailing duty
determinations with respect to fine
denier PSF from China and India² and
most recently final affirmative
antidumping duty determinations with
respect to China, India, Korea, and
Taiwan.³ The Commission, therefore, is

¹ *Fine Denier Polyester Staple Fiber From China, India, Korea, and Taiwan; Scheduling of the Final Phase of Countervailing Duty and Antidumping Duty Investigations*, 82 FR 56050, November 27, 2017.

² *Countervailing Duty Investigation of Fine Denier Polyester Staple Fiber From the People's Republic of China: Final Affirmative Determination*, 83 FR 3120, January 23, 2018; and *Countervailing Duty Investigation of Fine Denier Polyester Staple Fiber From India: Final Affirmative Determination*, 83 FR 3122, January 23, 2018.

³ *Fine Denier Polyester Staple Fiber from the People's Republic of China: Final Affirmative Determination of Sales at Less Than Fair Value*, 83

issuing a supplemental schedule for its
antidumping duty investigations on
imports of fine denier PSF from China,
India, Korea, and Taiwan.

The Commission's supplemental
schedule is as follows: The deadline for
filing supplemental party comments on
Commerce's final determinations is June
12, 2018; the staff report in the final
phase of these investigations will be
placed in the nonpublic record on June
21, 2018; and a public version will be
issued thereafter.

Supplemental party comments may
address only Commerce's final
antidumping duty determinations
regarding fine denier PSF from China,
India, Korea, and Taiwan. These
supplemental final comments may not
contain new factual information and
may not exceed five (5) pages in length.

For further information concerning
these investigations see the
Commission's notice cited above and
the Commission's Rules of Practice and
Procedure, part 201, subparts A and B
(19 CFR part 201), and part 207,
subparts A and C (19 CFR part 207).

Authority: These investigations are
being conducted under authority of title
VII of the Tariff Act of 1930; this notice
is published pursuant to section 207.21
of the Commission's rules.

By order of the Commission.

Issued: June 1, 2018.

Lisa Barton,

Secretary to the Commission.

[FR Doc. 2018-12169 Filed 6-5-18; 8:45 am]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

**Richard Hauser, M.D.; Decision and
Order**

On September 26, 2017, the Acting
Assistant Administrator, Diversion
Control Division, Drug Enforcement
Administration (DEA), issued an Order
to Show Cause to Richard Hauser, M.D.
(Registrant), of Clear Lake, Iowa. The
Show Cause Order proposed the
revocation of Registrant's DEA
Certificate of Registration No.
BH2140692 "pursuant to 21 U.S.C.
824(a)(5)." Government Exhibit (GX) 2

FR 24740, May 30, 2018; *Fine Denier Polyester Staple Fiber from the India: Final Affirmative Determination of Sales at Less Than Fair Value*, 83 FR 24737, May 30, 2018; *Fine Denier Polyester Staple Fiber from the Republic of Korea: Final Affirmative Determination of Sales at Less Than Fair Value*, 83 FR 24743, May 30, 2018; and *Fine Denier Polyester Staple Fiber from Taiwan: Final Affirmative Determination of Sales at Less Than Fair Value*, 83 FR 24745, May 30, 2018.

to Government's Request for Final
Agency Action (RFAA), at 1. For the
same reason, the Order also proposed
the denial of "any pending application
to modify or renew such registration."
Id.

With respect to the Agency's
jurisdiction, the Show Cause Order
alleged that Registrant is the holder of
Certificate of Registration No.
BH2140692, pursuant to which he is
authorized to dispense controlled
substances as a practitioner in schedules
II through V, at the registered address of
Hauser Clinic Consultation Services,
308 14th Street, Clear Lake, Iowa. *Id.*

Regarding the substantive ground for
the proceeding, the Show Cause Order
alleged that on April 28, 2017, the
Office of the Inspector General for the
U.S. Department of Health and Human
Services (HHS) notified Registrant of his
"mandatory exclusion from
participation in all Federal health care
programs for a minimum period of five
years pursuant to 42 U.S.C. 1320a-7(a)"
as a result of his guilty plea in the
United States District Court for the
Southern District of Iowa to two counts
of Health Care Fraud in violation of 18
U.S.C. 1347. *Id.* at 2. As a result, the
Order asserted that Registrant's
"[m]andatory exclusion from Medicare
is an independent ground for revoking
a DEA registration pursuant to 21 U.S.C.
824(a)(5)." *Id.* The Order further
contended that, although Registrant's
underlying conviction is "unrelated to
[Registrant's] handling of controlled
substances, DEA has nevertheless found
that the underlying conviction forming
the basis for a registrant's exclusion
from participating in federal health care
programs need not involve controlled
substances for revocation under 21
U.S.C. 824(a)(5)." *Id.* (citations omitted).

The Show Cause Order notified
Registrant of (1) his right to request a
hearing on the allegations or to submit
a written statement in lieu of a hearing,
(2) the procedure for electing either
option, and (3) the consequence for
failing to elect either option. *Id.* at 2-3
(citing 21 CFR 1301.43). The Show
Cause Order also notified Applicant of
his right to submit a corrective action
plan. *Id.* at 3-4 (citing 21 U.S.C.
824(c)(2)(C)).

The Government states that on
October 4, 2017, a DEA Diversion
Investigator (DI) served Registrant with
a copy of the Show Cause Order. RFAA,
at 3 (citing Declaration of DI attached as
GX 4). Specifically, a DI assigned to the
St. Louis Field Division's Des Moines
Resident Office stated in a declaration
that he was advised by Registrant's
Attorney that Registrant could be served
at his residence at 2310 20th Street, SW,